v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Series A Preferred Stock
Total Shareholders' Equity Attributable to Bruker Corporation
Common Stock
Treasury Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive (Loss) Income, Net of tax
Noncontrolling Interests in Consolidated Subsidiaries
Redeemable Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2024 $ 1,797.1   $ 1,781.2 $ 1.8 $ (1,237.2) $ 713.4 $ 2,406.7 $ (103.5) $ 15.9 $ 18.1
Balance (in shares) at Dec. 31, 2024       151,677,952            
Balance Treasury Shares at Dec. 31, 2024         30,778,879          
Increase (Decrease) in Stockholders' Equity                    
Stock options exercised 0.4   0.4     0.4        
Stock options exercised (in shares)       18,771            
Restricted Stock units vested (in shares)       24,999            
Stock based compensation 5.2   5.2     5.2        
Employee stock purchase plan 0.4   0.4     0.4        
Shares Repurchased (10.1)   (10.1)   $ (10.0) (0.1)        
Shares Repurchased (in shares)       (200,731) 200,731          
Dividends to common shareholders (7.7)   (7.7)       (7.7)      
Proceeds from the sale of (distributions to) noncontrolling interests, net (0.5)               (0.5)  
Consolidated net income (loss) 17.1   17.4       17.4   (0.3) (0.4)
Other comprehensive income (loss) 31.0   30.4         30.4 0.6 0.6
Balance at end of period at Mar. 31, 2025 1,832.9   1,817.2 $ 1.8 $ (1,247.2) 719.3 2,416.4 (73.1) 15.7 18.3
Balance ending (in shares) at Mar. 31, 2025       151,520,991            
Balance Treasury Shares at Mar. 31, 2025         30,979,610          
Increase (Decrease) in Stockholders' Equity                    
Stock options exercised 1.8   1.8     1.8        
Stock options exercised (in shares)       87,487            
Restricted Stock units vested (0.1)   (0.1)     (0.1)        
Restricted Stock units vested (in shares)       7,334            
Stock based compensation 5.3   5.3     5.3        
Employee stock purchase plan 3.7   3.7     3.7        
Employee Stock Purchase Plan (in shares)       100,115            
Dividends to common shareholders (7.6)   (7.6)       (7.6)      
Consolidated net income (loss) 6.0   7.6       7.6   (1.6) (1.7)
Certain other acquisitions                   28.3
Other comprehensive income (loss) (22.6)   (23.9)         (23.9) 1.3 2.5
Balance at end of period at Jun. 30, 2025 1,819.4   1,804.0 $ 1.8 $ (1,247.2) 730.0 2,416.4 (97.0) 15.4 47.4
Balance ending (in shares) at Jun. 30, 2025       151,715,927            
Balance Treasury Shares at Jun. 30, 2025         30,979,610          
Balance at beginning of period at Dec. 31, 2025 2,473.5   2,456.5 $ 1.8 $ (1,242.2) 1,414.6 2,361.8 (79.5) 17.0 36.8
Balance (in shares) at Dec. 31, 2025   2,760,000   152,143,041            
Balance Treasury Shares at Dec. 31, 2025         30,904,588          
Increase (Decrease) in Stockholders' Equity                    
Stock options exercised 1.1   1.1     1.1        
Stock options exercised (in shares)       48,580            
Restricted Stock units vested (0.1)   (0.1)     (0.1)        
Restricted Stock units vested (in shares)       31,467            
Stock based compensation 5.5   5.5     5.5        
Employee stock purchase plan 0.5   0.5     0.5        
Dividends to Series A Mandatory Convertible Preferred Stock (10.9)   (10.9)       (10.9)      
Dividends to common shareholders (7.7)   (7.7)       (7.7)      
Loan repayments from noncontrolling interest 0.2               0.2  
Consolidated net income (loss) 15.4   14.4       14.4   1.0 0.3
Certain other acquisitions 0.5   0.5       0.5     (0.8)
Other comprehensive income (loss) (11.0)   (10.7)         (10.7) (0.3) (0.5)
Balance at end of period at Mar. 31, 2026 2,467.0   2,449.1 $ 1.8 $ (1,242.2) 1,421.6 2,358.1 (90.2) 17.9 35.8
Balance ending (in shares) at Mar. 31, 2026   2,760,000   152,223,088            
Balance Treasury Shares at Mar. 31, 2026         30,904,588          
Increase (Decrease) in Stockholders' Equity                    
Stock options exercised 1.1   1.1     1.1        
Stock options exercised (in shares)       49,967            
Restricted Stock units vested (0.1)   (0.1)     (0.1)        
Restricted Stock units vested (in shares)       12,004            
Stock based compensation 5.2   5.2     5.2        
Employee stock purchase plan 3.2   3.2     3.2        
Employee Stock Purchase Plan (in shares)       67,908            
Dividends to Series A Mandatory Convertible Preferred Stock (10.9)   (10.9)       (10.9)      
Dividends to common shareholders (7.6)   (7.6)       (7.6)      
Consolidated net income (loss) (51.0)   (52.0)       (52.0)   1.0 0.1
Other comprehensive income (loss) (6.7)   (6.6)         (6.6) (0.1) (0.3)
Balance at end of period at Jun. 30, 2026 $ 2,400.2   $ 2,381.4 $ 1.8 $ (1,242.2) $ 1,431.0 $ 2,287.6 $ (96.8) $ 18.8 $ 35.6
Balance ending (in shares) at Jun. 30, 2026   2,760,000   152,352,967            
Balance Treasury Shares at Jun. 30, 2026 30,904,588       30,904,588